食欲素受体拮抗剂苏沃雷生对心脏术后早期睡眠结构的影响:一项随机对照试验
这项多中心、双盲、随机对照试验在两家大学附属心脏ICU纳入100例心脏术后成人患者,随机接受苏沃雷生20mg每日一次口服或安慰剂,从拔管后第一晚开始至出院或最长7天。主要终点为脑电图监测的入睡后觉醒时间(WASO),苏沃雷生组与安慰剂组无显著差异。总睡眠时间、补救药物使用、主观睡眠质量、谵妄发生率及无谵妄天数两组均无显著差异。
要点
- 心脏术后ICU成人患者中,苏沃雷生20mg每日一次口服组与安慰剂组夜间WASO中位数分别为200.7分钟与184.2分钟,差异无统计学意义(p=0.33)。
- 苏沃雷生组与安慰剂组总睡眠时间中位数分别为224.0分钟与253.0分钟,差异无统计学意义(p=0.92)。
- 两组补救药物(褪黑素、右美托咪定、苯二氮䓬类)使用、主观睡眠质量、谵妄发生率及无谵妄天数均无显著差异。
- 苏沃雷生从拔管后第一晚开始给药,持续至出院或最长7天,未显示对术后早期睡眠结构或谵妄的改善作用。
适用人群与场景
- 在两家大学附属心脏ICU接受心脏手术并体外循环后入住ICU的成人患者,拔管后开始研究干预。
诊断标准与关键阈值
- 睡眠起始定义为关灯后第一个30秒epoch被判读为快速眼动(REM)或非REM 1、2、3期;觉醒定义为持续30秒或以上的清醒期。
处置流程与药物剂量
- 苏沃雷生20mg每日一次口服,从拔管后第一晚开始,持续至出院或最长7天,以先发生者为准。
- 对照为安慰剂,给药方案相同。
研究设计与关键结果
- 多中心、双盲、随机对照试验,在两家大学附属心脏ICU纳入100例成人心脏术后患者,苏沃雷生组n=49,安慰剂组n=51。
- 主要终点夜间WASO中位数[四分位距]:苏沃雷生组200.7[112.1, 328.4]分钟 vs 安慰剂组184.2[80.4, 304.2]分钟,p=0.33,差异无统计学意义。
- 总睡眠时间中位数[四分位距]:苏沃雷生组224.0[112.0, 379.0]分钟 vs 安慰剂组253.0[68.0, 420.0]分钟,p=0.92,差异无统计学意义。
- 补救药物(褪黑素、右美托咪定、苯二氮䓬类)使用两组无显著差异;主观睡眠质量、谵妄发生率及无谵妄天数两组无显著差异。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心脏术后ICU成人患者,苏沃雷生20mg每日一次口服未能改善脑电图评估的入睡后觉醒时间或总睡眠时间,也未降低谵妄发生率。
- 该结果不支持在此类患者中常规使用苏沃雷生来改善术后早期睡眠或预防谵妄。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients recovering from cardiac surgery in the intensive care unit (ICU) do not sleep well. Commonly used sedative-hypnotic medications can disrupt sleep architecture and increase the risk of delirium in critically ill patients after surgery. The orexin receptor antagonist suvorexant, improves sleep onset and duration in patients with chronic insomnia. We hypothesized that suvorexant improves sleep onset and duration while also reducing the incidence of delirium after cardiac surgery.
METHODS: This multicentric, double-blind, randomized controlled trial was conducted at two university-based cardiac ICUs. One hundred adult patients were enrolled after admission to the ICU following cardiac surgery. Enrollment occurred between March 2020 and February 2025. Participants were randomized to receive either a once daily oral dose of suvorexant 20 mg or placebo. Treatment began on the first night after extubation and continued until hospital discharge or for a maximum of seven days, whichever occurred first. Sleep was recorded using an electroencephalography (EEG) monitor (SedLine, Masimo Corp., California, USA) on the first night after extubation and was scored blindly by an experienced registered polysomnographic technologist. The primary outcome was wakefulness after persistent sleep onset (WASO). Sleep onset was defined as the first 30-second epoch classified by rapid eye movement (REM) or non-REM stages 1, 2, 3 after lights off. Wakefulness was defined as an awake period of 30s or longer. Sleep questionnaires were administered and delirium screenings were conducted every morning until hospital discharge.
RESULTS: One hundred patients were randomized to receive suvorexant (n = 49) or placebo (n = 51). EEG analysis indicated that neither the median [inter-quartile range] nighttime WASO (200.7 [112.1, 328.4] minutes vs. 184.2 [80.4, 304.2] minutes; p = 0.33) nor total sleep time (224.0 [112.0, 379.0] minutes vs. 253.0 [68.0, 420.0] minutes; p = 0.92) differed significantly between the groups. There was no significant difference in rescue medication (melatonin, dexmedetomidine, benzodiazepine) utilization between the groups. Subjective sleep quality, incidence of delirium, and delirium-free days did not differ between the two groups.
TRIAL REGISTRATION NUMBER: Clinical Trials Registry no. NCT04092894, Registration Date 09/17/2019.
CONCLUSIONS: Among patients recovering in the ICU who underwent cardiac surgery with cardiopulmonary bypass, the suvorexant treatment did not affect wakefulness after sleep onset or post-operative delirium.
参考来源
- Wongtangman K, Reddy Janga S, Azimaraghi O, et al. Effect of the orexin receptor antagonist, suvorexant, on sleep architecture in the early postoperative period following cardiac surgery: a randomized controlled trial. Crit Care. 2026. PMID: 42337809. doi:10.1186/s13054-026-06151-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。